Peckham M J, Barrett A, Liew K H, Horwich A, Robinson B, Dobbs H J, McElwain T J, Hendry W F
Br J Cancer. 1983 May;47(5):613-9. doi: 10.1038/bjc.1983.99.
Between July 1979 and December 1981, 43 patients with metastatic germ-cell tumours (36 testicular non-seminomas and 7 testicular seminomas) were treated with 2-6 cycles of bleomycin, etoposide and cis-platin (BEP). Forty (93%) are alive, 37 (86%) with no evidence of disease. Of 36 men with testicular non-seminoma 30 (83.3%) are alive and disease-free at 8-38 months (median 17.0 months). In the latter group 25/28 (89.3%) who had had no prior irradiation are alive and disease-free. Fourteen non-seminoma patients had small volume metastases and 13 are in complete remission, as are 12/14 patients with bulky disease. All 7 patients with advanced seminoma are alive and disease-free. It is concluded that BEP is a well tolerated and effective first line treatment for patients with metastatic germ-cell tumours.
1979年7月至1981年12月期间，43例转移性生殖细胞肿瘤患者（36例睾丸非精原细胞瘤和7例睾丸精原细胞瘤）接受了2 - 6个周期的博来霉素、依托泊苷和顺铂（BEP）治疗。40例（93%）存活，37例（86%）无疾病证据。36例睾丸非精原细胞瘤男性患者中，30例（83.3%）在8 - 38个月（中位时间17.0个月）时存活且无疾病。在后一组中，28例中25例（89.3%）未曾接受过放疗，存活且无疾病。14例非精原细胞瘤患者有小体积转移灶，13例完全缓解，14例有大块病灶的患者中12例也完全缓解。所有7例晚期精原细胞瘤患者均存活且无疾病。结论是，BEP是转移性生殖细胞肿瘤患者耐受性良好且有效的一线治疗方案。
